| Document |
Document Title |
|
WO/2020/198815A1 |
The invention relates to the pharmaceutical industry, specifically to the production of a combination medicinal product for treating parasitic diseases, primarily helminth infestations, of various etiology, in particular to agents on the...
|
|
WO/2020/201440A1 |
Low doses of fluralaner or another isoxazoline derivative are administered to an animal such as a pet, typically a dog or a cat, preferentially by administration of a repeated dose, at regular intervals or at varying intervals, each dose...
|
|
WO/2020/202111A1 |
Disclosed herein are methods of treating or preventing infections associated with organisms, or preventing vector-borne diseases including Plasmodium infestation and/or malaria via delivery of one, two, or more systemic doses of an isoxa...
|
|
WO/2020/201191A1 |
The present invention relates to a method for recombinant production of a fusion protein comprising multiple malaria antigens for inducing immune responses comprising a combination of antibodies. In particular, the fusion proteins of the...
|
|
WO/2020/203763A1 |
The present invention provides: a compound represented by Formula (I) [wherein Q is a group or the like represented by Q1, Z represents an oxygen atom or the like, A1 represents CR4a or the like, A2 represents a nitrogen atom or the like...
|
|
WO/2020/193649A1 |
The invention relates to therapeutic applications, in particular to the treatment or prevention of diseases related to a protozoa infection (malaria, leishmaniasis) or a fungal infection, of 1,2-dioxolane-3,5-disubstituted compounds, and...
|
|
WO/2020/191091A1 |
This invention provides for compounds of the formula wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment...
|
|
WO/2020/188437A1 |
The present invention relates to compounds with a 5-(2-nitroethyI)-2,4,6- triaminopyrimidine structure, derivatised at the 1 position on the ethylene chain with heteroaromatic or phenyl-benzylether rings. The invention also relates to th...
|
|
WO/2020/190151A1 |
Hypersaline composition for use in a therapeutic, topical treatment of a fish infected with an ectoparasite and said treatment is safe to fish welfare, where the hypersaline composition comprises one of: - sea water salts and freshwater;...
|
|
WO/2020/188027A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2020/191361A2 |
The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs ...
|
|
WO/2020/189752A1 |
The purpose of the present invention is to provide an oral mucosa adhesion-type vaccine preparation, which is an oral mucosa adhesion-type preparation that allows a high-concentration drug solution to be adhered to the oral mucosa for a ...
|
|
WO/2020/183442A2 |
The present disclosure relates to phenylpropanoid saccharide esters, methods for the synthesis of libraries of phenylpropanoid saccharide esters with different degree and place of substitution in the sugar core, and their use as antimicr...
|
|
WO/2020/181138A1 |
A method of treating disease states associated with bacteria, a virus, a yeast, a mold, a fungus, a spore, a protozoa or a prion comprising a respiratory, oral, and internal delivery of hypochlorous acid (HOCI) via a nebulizer, an aeroso...
|
|
WO/2020/179902A1 |
The present invention addresses the problem of providing a malaria parasite growth inhibitor, and solves the problem by providing a malaria parasite growth inhibitor comprising a compound represented by general formula (I) or (II), or a ...
|
|
WO/2020/177128A1 |
Disclosed are a 2,6-diazaspiro[3.4]octane pyrimidine-hydroxamic acid compound and the use thereof. Specifically, the present invention relates to a compound as represented by formula I, or a pharmaceutically acceptable salt thereof, or a...
|
|
WO/2020/177129A1 |
Disclosed by the present invention are a 2,7-diaza-spiro[4.4]nonane hydroxamic acid pyrimidine compound, and a preparation and an application thereof. Specifically, the present invention relates to a compound represented by formula I, or...
|
|
WO/2020/180635A1 |
The invention relates to injectable compositions for combating liver fluke parasites in mammals, comprising clorsulon as the active agent. The invention also provides for an improved method for eradicating and controlling liver fluke par...
|
|
WO/2020/176887A1 |
The present invention relates to a milbemycin for use in control, treatment and/or prevention of infections with nematodes, preferably filariae, more preferably Dirofilaria immitis which are resistant to at least one other macrocyclic la...
|
|
WO/2020/175491A1 |
[Problem] To provide a pyridine N-oxide compound: that is superior in terms of pest control activities, particularly insecticidal activity and/or acaricidal activity among such activities; that is superior in terms of safety; and that ca...
|
|
WO/2020/174690A1 |
The present invention provides: a protein obtained by removing, from the amino acid sequence of the full-length surface antigen protein of a Babesia protozoa, the amino acid sequence of the N-terminal signal peptide thereof and the amino...
|
|
WO/2020/172220A1 |
Provided herein are anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies, and methods of producing the antibodies. Additionally provided are methods of treating or preventing malaria using the anti-CSP antibodies.
|
|
WO/2020/171129A1 |
The present invention provides: a compound which exhibits an excellent controlling effect against harmful arthropods and which is represented by formula (I) [in the formula, A1 denotes CR1b or the like, A2 denotes CR1c or the like, T den...
|
|
WO/2020/165559A1 |
The invention relates to a pharmaceutical composition comprising mebendazole and a strong or moderate cytochrome P450 1A2isoenzyme (CYP1A2) inhibitor, preferably fluvoxamine, thiabendazole or furafylline.
|
|
WO/2020/161450A1 |
Proteins derived from secretory/excretory products of Lepeophtheirus salmonis, including recombinant proteins, DNA encoding the proteins, vaccines and antigens comprising the proteins or the DNA, and uses thereof for the prevention or tr...
|
|
WO/2020/161221A1 |
The present invention relates to a method for the production of a (poly)hydroxylated pentacyclic triterpene composition including a 3-O-p-coumaroyl ester of tormentic acid from a plant suspension cell culture, to a pharmaceutical composi...
|
|
WO/2020/158632A1 |
The present invention provides functional water containing, as a functional component, a polyamine and/or a salt thereof, the total of the water content, the polyamine content, and the polyamine salt content being 95 wt% or more. The pol...
|
|
WO/2020/159444A1 |
The invention relates to a composition comprising insulin growth factor binding protein 7 (IGFBP7) for treating malaria or reducing the phenomenon of IRBC-endothelial cytoadherence. The composition can further comprise Von Willebrand Fac...
|
|
WO/2020/158889A1 |
The present invention provides a compound having an excellent control effect against harmful arthropods. A compound represented by formula (I) [wherein Q represents a group represented by Q1 or a group represented by Q2; Z represents an ...
|
|
WO/2020/156509A1 |
Provided are an anti-PD-1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Specifically, provided are a humanized anti-PD-1 antibody containing a specific CDR region and an antigen-binding fragment thereof...
|
|
WO/2020/152673A1 |
The invention is directed to Anti - Apicomplexan compositions, methods for producing the same, and methods for their use.
|
|
WO/2020/152067A1 |
Compounds of the formula (I): Q1-Q2-Q3, in which Q1, Q2 and Q3 have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovasc...
|
|
WO/2020/147097A1 |
A novel kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Also provided are a pharmaceutical composition comprising the compound of formula ...
|
|
WO/2020/144464A1 |
The invention relates to a trypanosomal vaccine, to pharmaceutical compositions comprising said vaccine and to their uses in vaccination to prevent trypanosomal infection in a mammal.
|
|
WO/2020/146625A1 |
Provided herein are engineered tuberous sclerosis complex 2 (TSC2) polypeptides in which the ability of a residue corresponding to a serine residue in a wild type TSC2 polypeptide to be phosphorylated is altered. In some cases, an engine...
|
|
WO/2020/144465A1 |
The invention relates to a trypanosomalvaccine, to pharmaceutical compositions comprising said vaccine and to their uses in vaccination to prevent trypanosomal infection in a mammal.
|
|
WO/2020/141155A1 |
The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have parti...
|
|
WO/2020/140197A1 |
Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composi...
|
|
WO/2020/139782A1 |
Disclosed herein, are methods of detecting one or more microbes in a subject having or suspected of having a demyelinating disease including multiple sclerosis. Also, disclosed herein are methods of treating subjects who are developing o...
|
|
WO/2020/139291A1 |
The present patent application discloses naphthalimide derivatives and in particular e.g. N-aryl-substituted naphthalimidopropylamine derivatives (i.e. 2-[3-(amino)propyl]-1H-benz[de]isoquinoline-1,3(2H)- dione derivatives) such as e.g. ...
|
|
WO/2020/132775A1 |
The invention relates to a natural organic composition with biocidal properties, comprising a combination of native Chilean plant extracts, essential oils and oxalic acid, useful for the treatment and prevention of ectoparasites and pest...
|
|
WO/2020/128473A1 |
The invention providesinter aliaa compound as defined herein and its use in the prevention or treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, e.g. cancer.
|
|
WO/2020/131629A1 |
The present invention provides compounds of formula (I): which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.
|
|
WO/2020/131631A1 |
The present invention provides compounds of formula (I): (I) which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.
|
|
WO/2020/128031A2 |
The present invention is directed to a coding RNA for a Malaria vaccine. The coding RNA comprises at least one heterologous untranslated region (UTR), preferably a 3'-UTR and/or a 5'-UTR, and a coding region encoding at least one antigen...
|
|
WO/2020/127765A1 |
The present invention is directed to crystalline phosphate salts of 5,6-diarylimidazo[2,1-b][1,3]thiazoles of Formula (I) or a solvate or hydrate thereof, wherein R = NH2 or H; A = CH or N; R' = CH2-1-Me-piperazin-4-yl or CH2NMe2; X = F,...
|
|
WO/2020/132218A1 |
A formulation for the dermal control of endoparasites comprising a macrocyclic lactone and method of use thereof.
|
|
WO/2020/127602A1 |
The present invention provides a conjugate of formula (I) and itsuse in methods of treatment, and also methods for delivering an active agent into a cell. The methods may be used to deliver an active agent into a nematode, flatworm, para...
|
|
WO/2020/115161A1 |
The present invention relates to compositions comprising an inactivated Mycobacterium or an immunogenic fraction thereof, for use in the prevention of an infection in a subject, wherein the infection is selected from the group consisting...
|
|
WO/2020/114166A1 |
A chloroquine gel and preparation method and application therefor. Chloroquine nano-microspheres contain water-soluble nano-microsphere carriers and chloroquine or chloroquine derivatives, and the mass ratio of the chloroquine or chloroq...
|
